Nancy Gray, PhD

Professor, Department of Pharmacology and Toxicology;
University of Arkansas for Medical Sciences,
Site Lead

University of Arkansas for Medical Sciences

Nancy M. Gray, Ph.D. is the director and president of BioVentures, LLC, the technology licensing office and business incubator for the UAMS.  She also is a professor in the Department of Pharmacology and Toxicology in the College of Medicine and co-directs a TL1 Health Sciences Innovation and Entrepreneurship (HSIE) Training Program for postdoctoral fellows. Since coming to UAMS in 2015 she has co-developed several entrepreneurship training programs and continues to serve these programs as teaching faculty and entrepreneurship mentor.  She is the director of the TRI-sponsored seminar series titled “Health Science Entrepreneurs: Innovators of Health Care” which has evolved into a collaborative effort with four other CTSA’s and an academic medical center.  She is a founder and director of the Health Sciences Entrepreneurship Boot Camp that is offered to Arkansas-based undergraduate and graduate students interested in non-academic careers in health sciences.  In 2018, the Boot Camp earned a second place Innovations in Research and Research Education Award from the Association of American Medical Colleges. Additionally, Gray serves as the Satellite Director on UAMS’s hub for the FFMI fastPACE Program designed by the University of Michigan Fast Forward Medical Innovation team and sponsored by TRI.

Prior to joining UAMS, Gray accumulated more than thirty years of experience in biomedical industries, including medicinal chemistry research, management of pharmaceutical research and development, and business operations. In the past, she led numerous transactions, including mergers and acquisitions, strategic alliances, joint ventures, minority investments, technology licenses and divestitures for the life sciences, engineering, and environment and energy businesses. In her past roles at various startups, she was responsible for authoring the business plans that successfully raised an aggregate $126 million in venture capital financing.  Nancy’s research work on central nervous system diseases resulted in three products being accepted for clinical development in five years. She was also instrumental in the discovery and development of two marketed second generation antihistamines, Allegra® and Xyzal®. Nancy is the inventor on 32 issued U.S. patents and the author of 23 publications.  She received her bachelor’s degree in chemistry from Bucknell University and her doctorate in medicinal chemistry from the University of Illinois.